Study Of The Expression And The Relationship Between Galectin-3 And Serum VEGF In Cervical Carcinoma

【Objective】Expression of Galectin-3 was detected and levels of serum Galectin-3 and VEGF were measured in cervix with different pathological changes. To preliminarily explore the role of Galectin-3 in cervical carcinoma and the correlation to clinical feature, as well as the relationship between serum Galectin-3 and VEGF. In order to find a valuable marker for condition monitoring in cervical carcinoma and provide theoretical basis of therapeutic target at same time.【Method】Collecting 10 cases of normal cervical tissues, cervical intraepithelial neoplasia and invasive cervical carcinoma stageⅠto stageⅢrespectively. Immunohistochemistry SP method is used to detect the expression of Galectin-3 protein in each group tissues and Enzyme-Linked Immunosorbent Assay (ELISA) is used to determine the levels of serum Galectin-3 and VEGF. To compare the different positive rates of Galectin-3 in multiple groups were using the Chi-square test or Fisher probabilities in 2×2 table if necessary. Using nonparametric statistics Kruskal-Wallis rank sum test in multi-group serum levels of Galectin-3 and using nonparametric statistics Mann-Whitney U test between two groups. The correlation between the serum Galectin-3 and VEGF in cervical carcinoma used Spearman analysis. P<0.05 means it has statistical significance.【Results】1. Immunohistochemistry showed:Galectin-3 were expressed in the group of normal cervical, cervical intraepithelial neoplasia and invasive cervical cancer group. The positive rate of Galectin-3 expression was not the same in five groups. The positive rates of Galectin-3 were 90% in cervical carcinoma stageⅡandⅢgroups. It's higher than the normal cervical group (positive rate:40%),χ2=5.495,P=0.029, the difference is statistical significance.30 cases of cervical carcinoma, which were 19 cases of high grade carcinoma and were 11 cases of low grade carcinoma. The positive rates were 84.21% and 81.82% respectively.28 cases of squamous carcinoma,2 cases of adenocarcinoma and adenosquamous carcinoma, the positive rates were 85.71% and 50.00%. The tumors of 11 cases were≤2cm, the positive rate was 63.64%; the tumor of 19 cases were>2cm, the positive rate was 94.75%. The depth of cervical stromal invasion≤1/2 group, the positive rate was 66.67%. In 8 cases, cervical pathology showed the depth of cervical stromal invasion>1/2, the positive rate was 87.50%. The positive rate of Galectin-3 expression were not statistically different in groups of histological differentiation, different pathological types and cervical stromal invasion (P> 0.05). It had statistically significant in group of tumor sizes (x2=4.690, P=0.047). The age of patients (x2=0.932, P=0.329) and ethnicity (x2=0.644, P=0.433) were no significant difference.2. ELISA showed:the levels of serum Galectin-3 respectively were 0.89±0.05 ng/ml,0.89±0.04 ng/ml,0.88±0.04 ng/ml,0.91±0.05 ng/ml,1.72±0.46 ng/ml in normal cervical, cervical intraepithelial neoplasia and cervical carcinoma stageⅠ,Ⅱ,Ⅲgroup. The levels of serum Galectin-3 were incomplete identical among five groups. Serum Galectin-3 levels of SCC stageⅢgroup was significantly higher than the group of normal cervical, cervical intraepithelial neoplasia, cervical carcinoma stageⅠandⅡ(P<0.05), there were significant differences. Serum Galectin-3 levels (1.29±0.52 ng/ml), which the group of tumors>2cm is higher than group of tumors≤2cm (0.97±0.31 ng/ml), x2=4.690, P=0.047, P<0.05, the difference is significantly. But no significant difference in different pathological grade, pathological type, depth of cervical stromal invasion, age and ethnicity (P >0.05)3. In the group of normal cervical, cervical intraepithelial neoplasia, cervical carcinoma stageⅠ,Ⅱ,Ⅲ, the levels of serum VEGF were 405.30±100.90 pg/ml, 448.80±60.46pg/ml,510.01±81.75pg/ml,529.43±69.81pg/ml,577.24±125.15pg/ml. The VEGF levels (Z=15.572, P=0.004) were incomplete identical among five groups. Serum VEGF levels in groups of cervical carcinoma stageⅠ,Ⅱ,Ⅲwere higher than normal cervix (P＜0.05), there is significant differences. Serum Galetin-3 was positively correlated with VEGF in cervical carcinoma (r=0.321, P =0.042)【Conclusions】Expression of Galectin-3 in cervical carcinoma stageⅡ,Ⅲtissues were significantly higher than others. The levels of serum Galectin-3 shows a high expression in cervical carcinoma stage III. High Galectin-3 expression was significantly associated with tumor sizes, but not related to histological differentiation, pathological type, depth of cervical stromal invasion, age and ethnicity. The differential expression of Galectin-3 suggested that Galectin-3 related to occurrence and progression of cervical carcinoma. It will become a valuable marker for detecting the progression in cervical carcinoma. The serum Galectin-3 was positively correlated with serum VEGF, they are through angiogenesis together to promote progression in the cervical carcinoma.